Investor alert: levi & korsinsky, llp reminds investors of an investigation involving possible securities fraud violations by the board of directors of acorda therapeutics, inc.

New york--(business wire)--levi & korsinsky announces it has commenced an investigation of acorda therapeutics, inc. (nasdaqgs:acor) (“acorda” or the “company”) concerning possible violations of federal securities laws. on november 15, 2017, acorda revealed it had ceased enrolling new patients in its phase 3 trial of its parkinson’s treatment due to patient deaths. to obtain additional information, go to: http://www.zlkdocs.com/acor-info-request-form-6067 or contact joseph e. levi, esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. levi & korsinsky is a national firm with offices in new york, california, connecticut and washington d.c. the firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. attorney advertising. prior results do not guarantee similar outcomes.
ACOR Ratings Summary
ACOR Quant Ranking